211 related articles for article (PubMed ID: 21436071)
1. Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion.
Negre O; Fusil F; Colomb C; Roth S; Gillet-Legrand B; Henri A; Beuzard Y; Bushman F; Leboulch P; Payen E
Blood; 2011 May; 117(20):5321-31. PubMed ID: 21436071
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy for beta-thalassemia.
Malik P; Arumugam PI
Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
5. A Novel BaEVRless-Pseudotyped γ-Globin Lentiviral Vector Drives High and Stable Fetal Hemoglobin Expression and Improves Thalassemic Erythropoiesis
Drakopoulou E; Georgomanoli M; Lederer CW; Kleanthous M; Costa C; Bernadin O; Cosset FL; Voskaridou E; Verhoeyen E; Papanikolaou E; Anagnou NP
Hum Gene Ther; 2019 May; 30(5):601-617. PubMed ID: 30324804
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.
Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA
Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779
[TBL] [Abstract][Full Text] [Related]
7. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.
Imren S; Payen E; Westerman KA; Pawliuk R; Fabry ME; Eaves CJ; Cavilla B; Wadsworth LD; Beuzard Y; Bouhassira EE; Russell R; London IM; Nagel RL; Leboulch P; Humphries RK
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14380-5. PubMed ID: 12391330
[TBL] [Abstract][Full Text] [Related]
8. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.
Malik P; Arumugam PI; Yee JK; Puthenveetil G
Ann N Y Acad Sci; 2005; 1054():238-49. PubMed ID: 16339671
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
Persons DA; Allay ER; Sawai N; Hargrove PW; Brent TP; Hanawa H; Nienhuis AW; Sorrentino BP
Blood; 2003 Jul; 102(2):506-13. PubMed ID: 12663444
[TBL] [Abstract][Full Text] [Related]
10. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.
Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW
Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice.
Tan M; Qing K; Zhou S; Yoder MC; Srivastava A
Mol Ther; 2001 Jun; 3(6):940-6. PubMed ID: 11407908
[TBL] [Abstract][Full Text] [Related]
12. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.
Rivella S; May C; Chadburn A; Rivière I; Sadelain M
Blood; 2003 Apr; 101(8):2932-9. PubMed ID: 12480689
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.
Negre O; Bartholomae C; Beuzard Y; Cavazzana M; Christiansen L; Courne C; Deichmann A; Denaro M; de Dreuzy E; Finer M; Fronza R; Gillet-Legrand B; Joubert C; Kutner R; Leboulch P; Maouche L; Paulard A; Pierciey FJ; Rothe M; Ryu B; Schmidt M; von Kalle C; Payen E; Veres G
Curr Gene Ther; 2015; 15(1):64-81. PubMed ID: 25429463
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
[TBL] [Abstract][Full Text] [Related]
15. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.
Puthenveetil G; Scholes J; Carbonell D; Qureshi N; Xia P; Zeng L; Li S; Yu Y; Hiti AL; Yee JK; Malik P
Blood; 2004 Dec; 104(12):3445-53. PubMed ID: 15292064
[TBL] [Abstract][Full Text] [Related]
16. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy.
Persons DA; Allay ER; Sabatino DE; Kelly P; Bodine DM; Nienhuis AW
Blood; 2001 May; 97(10):3275-82. PubMed ID: 11342459
[TBL] [Abstract][Full Text] [Related]
17. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.
Cavazzana-Calvo M; Payen E; Negre O; Wang G; Hehir K; Fusil F; Down J; Denaro M; Brady T; Westerman K; Cavallesco R; Gillet-Legrand B; Caccavelli L; Sgarra R; Maouche-Chrétien L; Bernaudin F; Girot R; Dorazio R; Mulder GJ; Polack A; Bank A; Soulier J; Larghero J; Kabbara N; Dalle B; Gourmel B; Socie G; Chrétien S; Cartier N; Aubourg P; Fischer A; Cornetta K; Galacteros F; Beuzard Y; Gluckman E; Bushman F; Hacein-Bey-Abina S; Leboulch P
Nature; 2010 Sep; 467(7313):318-22. PubMed ID: 20844535
[TBL] [Abstract][Full Text] [Related]
18. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.
Papanikolaou E; Georgomanoli M; Stamateris E; Panetsos F; Karagiorga M; Tsaftaridis P; Graphakos S; Anagnou NP
Hum Gene Ther; 2012 Jan; 23(1):15-31. PubMed ID: 21875313
[TBL] [Abstract][Full Text] [Related]
19. Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation.
Boulad F; Wang X; Qu J; Taylor C; Ferro L; Karponi G; Bartido S; Giardina P; Heller G; Prockop SE; Maggio A; Sadelain M; Rivière I
Blood; 2014 Mar; 123(10):1483-6. PubMed ID: 24429337
[TBL] [Abstract][Full Text] [Related]
20. Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients.
Preedagasamzin S; Nualkaew T; Pongrujikorn T; Jinawath N; Kole R; Fucharoen S; Jearawiriyapaisarn N; Svasti S
Biochem Biophys Res Commun; 2018 Apr; 499(1):86-92. PubMed ID: 29550480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
